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Mitochondria originated during a key endosymbiotic event, when an enveloped 
bacterium or invasive parasite adjusted to its intracellular surroundings and formed the 
first eukaryotic cell. The symbiote evolved into a specialist organelle supplying the vast 
majority of a cell‟s ATP energy supply as well as regulation of cellular differentiation, 
cell death, the cell cycle, and cell growth. Due to its double layered membranes and 
separate DNA control systems, it has proved an elusive target for medicines, and is 
responsible for a host of diseases and may be a key contributor to the aging process.  
Mitochondrial disorders, though a diverse family ranging from cardiac diseases to 
a subset of Parkinson‟s syndrome, individually affect relatively small populations and 
may therefore fall under the purview of the Orphan Drug legislation enforced by the Food 
and Drug Administration. While no viable delivery mechanism for macromolecules 
larger than proteins currently exists for the inner mitochondrial matrix, several academic 
research papers suggest that the unique morphological challenges of mitochondria may 
be overcome. A survey of these approaches is presented within the context of 
mitochondrial structure, and a path towards economical drug development via the Orphan 
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INTRODUCTION TO MITOCHONDRIA 
Mitochondria, along with chloroplasts, share the unique property of being the 
only subcellular organelles with DNA independent of the nucleus. Two theories were 
proposed account for this non-nuclear DNA; that it had migrated from the nucleus itself, 
or was the result of an event where one anaerobic proto-eukaryotic cell engulfed another 
aerobic bacterium, known as primary endosymbiosis and championed by Lynn Margulis
1
 
despite much skepticism. A conclusive meta-study in 1992
2
 found the endosymbiotic 
theory compelling, and it is accepted today as one of the seminal moments in the 
formation of complex life.  Evidence of the mitochondrion‟s bacterial past abound, such 
as its reliance on binary fission for replication, double membrane outside structure, 
circular DNA structure, lack of histone proteins, and non-eukaryotic ribosomes along 
with non-eukaryotic amino acid codon triplet translation
3
. 
Recent sequencing work finds that Rickettsia prowazekii is the most genetically 
similar known relative of mitochondria
4
, implying the possibility that endosymbiosis was 
not a chance event of a prey bacterium surviving attempted consumption by a predator 
proto-eukaryote, but that of an invasive, perhaps flagellated parasite that adopted a 
mutualistic relationship after successfully entering the proto-eukaryotic cell.  
Regardless of the nature of the endosymbiotic event, the bacterial origins of 
mitochondria are seminal in its evolution, function, morphology, and prospects as a 
therapeutic target.  1.5 billion years of coevolution has stripped the organelle of virtually 
all of its original genes, transferring them to the nucleus or removing them entirely
5
. 
Varied mitochondrial functions separate from its canonical role as the primary aerobic 
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energy producer of the cell have developed, as a result of protein import into the 
mitochondria and its incorporation into cell cycle regulation. 
 
Mitochondrial Functions 
As the organelle responsible for both the citric acid cycle and oxidative 
phosphorylation (OXPHOS), mitochondria produce the vast majority of ATP energy 
available to a healthy cell
6
. Mitochondrial genes concern themselves with the OXPHOS 
process, the means by which ATP is processed due to the oxygen atom‟s singular ability 
to accept H+ ions. Put simply, the organelle‟s primary duty is to provide a series of 
„water mills‟, whereby ions flow down an electrical gradient. The mills provide the 
motive power with which ATP synthase can attach a third phosphorus atom to ADP, 
allowing for the formation of an ATP energy carrier used ubiquitously throughout the 
cell. Interruption of this process, such as through asphyxiation, results in quick cell death 
– even more rapidly with those cells such as neurons with high energy requirements. 
3 
 
Figure 1: Electron Transport Chain
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As may be seen in the above diagram (Figure 1), the proteins Complex I (NADH), 
Complex III (Cytochrome b-c complex), and Complex IV (Cytochrome C Oxidase 
complex) exist to pump H+ ions across the inner mitochondrial membrane barrier, with 
Complex IV reducing oxygen to water. This forms a voltage gradient, whereby H+ ions 
seek to return to the matrix. This is facilitated via Complex V (ATP Synthase), a complex 
radial protein analogous to the watermill. Driving a rotating subunit akin to a radial 
piston, the proton flow provides the force allowing the enzyme to combine ADP and 
phosphate to form ATP
8
.  
Mitochondria are capable of a surprising amount of autonomous and cell-directed 
morphogenesis. Mere contact between two mitochondria can set a process of fusion in 
motion, incidentally providing evidence that macromolecular import (in this case, 
mitochondrial mtDNA plasmids) into these structures is indeed possible
9
. Cristae are able 
to invaginate and deform, and there is some evidence that the quantity of Complexes I 
through V are not static
10
. As with bacteria, mitochondrial replication takes place via 
fissioning; however the signals are nuclear in origin. Upregulation by mitochondrial 
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fission factor Mff and its associated Drp1 protein, and downregulation by Mitofusin 1, 
regulate mitochondrial cell count. With all these processes at its disposal, a cell can 
modulate energy output based on both its differentiated role and changing energy 
demands.  
Evolution has curiously co-opted Cytochrome c, present within the inter-
membrane space and the structural unit associated with Complex IV, into a cell death 
signaling device, whereby pro-apoptotic factors result in translocation of increased levels 
of Ca2+ from the endoplasmic reticulum into the cell and mitochondria. This triggers 
Cytochrome c release into the cell cytosol, causing caspase release. A positive feedback 
ensues that causes calcium to soar to cytotoxic levels. The recruited caspases function as 
complexes that actively destroy cellular structures and complete apoptosis
11
. Common 
causes of the initial Cytochrome c release include cellular infection and DNA damage; 
the pathway as a result is critical in cancer defense. It has been speculated that one of the 
causes of the Warburg effect, whereby cancerous cells shut down mitochondrial 
respiration and rely on glycolysis alone despite oxygen availability, is the reduction of 
voltage differentials in the mitochondria and inhibition of Cytochrome c release
12
. Any 
macromolecular delivery system will have to contend with the inter membrane space as a 
result. Rupture of the outer membrane could trigger the above process rendering an 
inadequately designed vector cytotoxic.  
Mitochondria are also implicated in pyrimidine and heme synthesis; disrupted 
organellar function reduces the rate-limiting enzymes that power these processes. 







Consisting of a circular double-stranded DNA (mtDNA) 16,569 base pairs long, 
and covered by a histone-like mitochondrial transcription factor A protein (TFAM), an 
average of 5 copies
14
 of mtDNA reside within the inner matrix of a mitochondrial 
organelle. The DNA encodes for very few functional proteins, along with a control 
region, and tRNA and ribosomal machinery to support transcription and translation, 
respectively. All mtDNA is maternally inherited, as sperm mitochondria are actively 
destroyed during insemination to prevent chimerism.  
 
                                         Figure 2: Mitochondrial DNA
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Mammalian mitochondrial DNA, regardless of species complexity, appears to 
retain 13 core protein-coding genes
16
 (Figure 2), while being relieved of all other protein 
synthesis by the nucleus. This strongly implies the functional importance of having 
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synthesis of these 13 proteins occur within the mitochondrial inner matrix itself and not 
within the nucleus. It may be speculated that either their structural functions cannot be 
replicated through mitochondrial import, or up and down-regulation of their ubiquity in 
the mitochondrial structure cannot be modulated with adequate speed from the nucleus, 
or both.  
These genes may be grouped in 5 distinct components of aerobic energy 
production: complexes I, III and IV, and the ATP synthase enzyme in complex V
17
. 
Complex II indirectly contributes to energy production via catalyzing succinate to 
fumarate.  
Critically, mtDNA suffers from a considerably higher mutation and particularly 
deletion rate than nuclear nDNA. This may be due to several factors. DNA polymerase 
gamma (POLG), encoded in the nucleus, may be less able to faithfully replicate guanine-
dominated mtDNA, resulting in base-pair mismatches
18
. Much of the extensive protein 
machinery within the nucleus for mutation detection and repair appears unavailable 
within the mitochondrial inner matrix. This weakness is compounded by local free radical 
production during the OXPHOS process.  
 
Table 1: Mitochondrial Genes  
Component Category Gene 




Cytochrome b-c  
MT-CYB 
Complex IV Cytochrome c Oxidase MT-CO[1,2,3] 






Structure and Membrane Composition 
Along with chloroplasts, mitochondria feature a double membrane enclosing an 
inter-membrane space. The inner membrane forms a series of folds, called cristae, greatly 
increasing the surface area of the inner matrix within it. As described later, this enlarged 
surface area serves enhances the voltage gradient that powers energy production. Cells 
with greater energy demands, such as muscle tissue, increase the surface area of this 
reaction via a greater number of cristae as well as a higher mitochondrial count. A 
variable number of mtDNA molecules are contained within the matrix, along with 
ribosomal protein assemblies, ATP synthase, and granules that appear to modulate inter-




                                       Figure 3: Mitochondria Cross-Section20 
 
 
The inter-membrane space (Figure 3), acidic due to proton import from the 
matrix, retains structural and signaling proteins from the cytosol as well as mtDNA 
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proteins and Hsp70 protein stabilizers. It also serves as a store of the small heme protein 
Cytochrome c discussed later
21
. 
The outer membrane has a similar protein-to-phospholipid ratio to that of the 
eurkaryotic plasma membrane (50:50 in weight), while containing integral porins that 
allow sub-5,000 dalton molecules to pass through. Larger molecules require 
mitochondrial membrane transport proteins to shuttle across the membrane, referred to as 
the TIM/TOM complex
22
.  Signaling sequences recognized by the Translocase of the 
Outer Membrane complex (TOM) cause active transport of the molecule into the 
intermembrane space and further to the Translocase of the Inner Membrane complexes 
(TIM) known as TIM23 and TIM22, located nearby, facilitating entry of the protein via 
ATP into the inner matrix where it can unfold. Hsp70 stabilizes the molecule, preventing 
Hsp60-mediated unfolding until arrival at the inner matrix, while processing peptidases 
cleave the signaling pre-sequences. The TIM/TOM system (Figure 4) allows for circa 
1,500 mitochondria-related proteins encoded by the nucleus to localize; mutations in this 
complex are usually fatal.   
 
                          Figure 4: Mitochondrial Protein Import
23









Unlike that of the outer membrane, the mitochondrial inner membrane‟s protein-
to-lipid concentrations are 80:20; similar to bacteria and further evidence for the 
endosymbiotic theory. Along with TIM structures, Complexes I through V belonging to 
the electron transport chain dot its surface. Multimeric mitofilin proteins present 
throughout the membrane stabilize the cristae. High protein levels reflect this structural 
backbone as well as the various permeable membrane-spanning proteins needed for 
respiration and proton exchange with the inter-membrane space
24
. 
As a result of this double-layered membrane and its size and signaling 
requirements for molecular import, only proteins with correct amino acid signaling 
sequences assembled in the cytosol are available to the inner matrix. This presents one of 
the key challenges to mitochondrial druggability – how to effectively import 
macromolecules without signaling sequences, or how to design therapeutic molecule 





Nuclear and Mitochondrial Origins 
Recognition of the role of mitochondria in a plethora of diseases has been a fairly 
recent phenomenon. As may be seen in the table below and consistent with the role of the 
organelle, mitochondrial diseases are preferentially implicated in tissues with high energy 
demand: the brain, heart, liver, skeletal muscles, respiratory and endocrine, and kidney 
systems. A slew of symptoms may range from motor control loss, general muscle 
weakness and pain, exercise intolerance, gastro-intestinal indications, failure to thrive and 
poor growth, heart and liver disease, diabetes, seizures, to a weakened immune system
25
. 
Ragged red fibers, where clumps of diseased mitochondria accumulate in the 
subsarcolemmal region of muscle fiber
26
, are identifiable under the microscope for a 
large number of the diseases. While 13 proteins are encoded by mtDNA, nearly 3,000 
genes and 1,500 proteins from the nucleus have been discovered
27
. The field is in its early 
stages and often the root genetic locations of mitochondrial dysfunction are not fully 
known. More than 36 diseases have been identified; for the sake of brevity, the most 
understood syndromes are listed. Those with maternally-inherited characteristics strongly 
implicate mtDNA. Population sizes are based either on published figures or on 
extrapolations of published sample population rates. Table 2a identifies larger diseases 







Table 2a: Diseases with Mitochondrial Pathologies  
Disease Notes Estimated U.S. 
Population 
Alzheimer‟s Disease Amyloid-β inhibition of 















Varied causes. Observed 
loss of mitochondrial 




~ 500,000 deaths 
annually 
CKD: Chronic Kidney 
Disease 
Varied causes. Apparent 
up-regulation of nuclear 











































Table 2b: Diseases due to Mitochondrial Malfunction  




Lactic Acidosis, Stroke 
Mutant mtDNA. May be 
widely under-diagnosed, 
with mild to moderate 









Inherited Diabetes and 
Deafness 
May be mis-diagnosed 
as regular Type 1 or 





~130,000 - 700,000  
0.5% to 2.8% of Type 




mtDNA mutations of 
Complex I 






Leigh‟s Disease mtDNA or nDNA 
mutations.  
~ 7,500 












~ 750 ? 
KSS: Kearns-Sayre 
Syndrome 














Related to Kearns-Sayre 







Beyond the above figures, it is estimated that 1 in 4,000 children in the United States will 
develop mitochondrial disease by age 10, giving an affected U.S. youth population of 
circa 12,500
42
. Some children are classified within the above disease framework and 
others are labeled generally as a „failure to thrive‟. Mitochondrial myopathy, defined as 
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genetic mutations that directly affect the electron transport chain, may affect 1 in 8,000 in 
the general population
43
, giving an affected U.S. population of 37,500.  
Notably, most diseases whose root causes lie in mtDNA mutations alone such as 
LHON and Leigh‟s disease feature small population sizes. It may be speculated that 
strong selection pressure has kept rates low as maternal carriers would be at a 
multigenerational procreative disadvantage. Diseases with significant population counts, 
namely MIDD and MELAS, are survivable and may not have encountered such pressure.  
As with much of medicinal research, causality in the progression of a disease may 
be very unclear. Does decreased mitochondrial function initiate malaise, or is it a 
byproduct? If a byproduct, does it then exacerbate the condition? If so, is the organelle 
worth targeting by a therapeutic, or ought instead the focus to be on mitochondrial genes 
within the nucleus?   
Alzheimer‟s and Parkinson‟s disease bear further investigation and are the focus 
of much mitochondrial research. Mice engineered to overexpress amyloid-β clusters, a 
hallmark of Alzheimer‟s, then had neural mitochondria excised at various life stages. 
Well before old age, these synaptic mitochondria had accumulated five times the amount 
of clusters as non-neural mitochondria and had compromised energy production as a 
result
44
. Complex IV‟s functioning appears to be particularly disrupted by amyloid-β
45
, 
and inhibition of correctly functioning mitochondrial enzymes appears to raise reactive 
oxygen species (ROS) that wreak further havoc on the mitochondria and beyond. 
Systemically, a significant decrease of energy metabolism in the frontal and temporal 
lobes of the brain is common. This leads to senescence and death of the neurons and 





More specifically to mtDNA and to potential treatment of Alzheimer‟s and other 
diseases, ROS production leads to oxidation of mtDNA itself
47
. Control regions of 
mtDNA have shown elevated mutation rates in afflicted patients. A potential treatment of 
later-stage Alzheimer‟s could involve the provision of intact mtDNA into damaged 
mitochondria, while it may be speculated that amyloid-β-countering molecules could 
address earlier stages of the disease. Both require an as-yet-undeveloped mitochondrial 
delivery system. 
An alternative theory postulates that a root cause of Alzheimer‟s is the disruption 
of mitochondrial motility. Normally functioning mitochondria in tissues with high energy 
demand may actively travel via the microtubule infrastructure to regions with high Ca2+ 
concentrations, such as axonal or dendritic regions of neurons. Defects in protein 
regulation of mitochondria-endoplasmic reticulum interactions in regions termed 
mitochondria-associated membranes (MAM)
48
 may render mitochondria unable to escape 
their association with the ER and are therefore unable to travel to sites with high energy 
demands and/or other mitochondria-mediated requirements
49
.  
Parkinson‟s Disease appears to demonstrate nuclear-encoded mitochondrial gene 
malfunction. A root cause of some Parkinson‟s may relate to 10 sets of genes including 
Parkin and PINK-1, controlled by master regulator PCG-1α
50
. As a result, enzymes 
critical to OXPHOS are suppressed and neurons abandon mitochondrial respiratory 
pathways with a concomitant energy supply loss, leading to widespread death of 
dopamine-producing cells within the brain.  
In a strikingly similar manner to Alzheimers, but involving Complex I and III 





. A downward spiral occurs: increased malfunction, leading to increased 
ROS production, resulting in damage to the surviving OXPHOS systems, attendant 
malfunction, and so on. Oxidative damage is not restricted to the mitochondria and can 
damage other cellular organelles, proteins, lipids, and nuclear nDNA. A potential 
treatment could redress this enzymatic balance by artificially increasing the amount of 
Parkin-type enzymes; this may be accomplished by remodulating PCG-1α or introducing 
those enzymes externally via medication. A recent study found widespread DNA repair 




MELAS and MIDD sufferers, the other large mitochondrially-derived disease 
populations, may suffer from misdiagnosis as symptoms are often identical to similar, 
more common diseases
53
, and severity may be dependent on the relative populations of 
corrupted and functional mtDNA within the target tissues. Improved online genealogic 
tools and more widespread genetic counseling may firm up the estimated numbers 
presented in this paper as well as open up these populations to tailored therapy.  
Cardiomyopathy and heart disease, the primary cause of death in the United 
States, is due to an exhaustive range of genetic, environmental, and lifestyle factors. 
Recently mitochondrial abnormalities have been implicated as the sole cause or a 
contributing factor towards incidences of the disease
54
. Decreased metabolic rates and 
increased ROS production are implicated. Online tools such as MITOMASTER, 
combined with mtDNA sequencing and phylogenetic data could improve diagnosis
55
. 
Chronic Kidney Disease appears to have a similar relationship to mitochondria. 
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The relationship between mitochondria and cancer is extensive and beyond the 
scope of this paper. Manipulation of mitochondria disabled by the Warburg effect may 
provide a directed apoptosis-inducing weapon. High incidences of mtDNA mutations in 
cancerous cells have been observed
56
. A class of molecules termed „mitocans‟
57
 are 
specifically lethal to mitochondria and induce cell death, and could be utilized as an anti-
cancer strategy.  
As is implied by the estimated prevalence rates in Tables 2a and 2b, maternally-
inherited mtDNA mutations that are homoplasmic – where all mtDNA molecules share 
the same defect – are extremely rare in surviving populations. Far more likely is the 
condition of heteroplasmy, where a certain percentage of mtDNA remain wild-type while 
the rest entertain one or more defects
58
.  This wt/- mtDNA ratio may be resilient; as many 
as 70-80% of mtDNA may be corrupted
59
 before a threshold is reached and 
mitochondrial dysfunction ensues. A logical therapeutic approach would be to redress 
this heteroplasmic ratio by either the provision of wild-type mtDNA or the selective 
destruction of damaged mtDNA.  
Alternatively, upregulation of mitochondrial fission activity could disperse the 
population of wild-type mtDNA within cellular mitochondria and alter the ratio as well, 
and possibly segregate salvageable mitochondria from those destined for mitophagy. 
After this triage, fission of functioning mitochondria could repopulate the cell. Disruption 








Mitochondria and Aging 
A common paradigm in the above discussed diseases is the starving of the cell 
due to insufficient energy production; whether the cause or a deleterious effect of a 
syndrome, an ATP deficit may directly result in cellular senescence and death. This is 
aggravated in cells with high energy requirements and it is no coincidence that 
mitochondrial disorders affect the central nervous or cardiovascular systems. A natural 
question arises: if cardiomyopathy is the leading cause of death in aged populations, and 
Alzheimer‟s & Parkinson‟s the leading neurological syndromes of the old, why do these 
diseases appear primarily in the elderly? 
The mitochondrial theory of aging attempts to unify the diverse strands of 
evidence, by postulating that the inadequate repair machinery available to mtDNA, 
combined with its proximity to the OXPOHOS site of ROS production, leads to 
progressive, inevitable mtDNA mutation and deletion. Given that fully 93% of mtDNA is 
functional coding without introns, and even displays overlap of genes, virtually any point 
mutation will be deleterious. Either there will be a defect in Complex I, II, or IV 
formation through disruption of those structural genes, or a defect in the ribosomal 
machinery necessary to translate them, or a defect in the tRNA necessary to translate the 
proteins, or a defect in the control mechanism. 
Redundancy only exists in the mtDNA copy number: if sufficient mtDNA 
molecules within mitochondria are intact for a particular gene, they may be expressed in 
wild-type in adequate quantity to maintain mitochondrial function. Virtually any recoding 
of the molecule stands a high chance of being phenotypic; compounding the effect is the 
18 
 
proximity of mtDNA to the source of ROS in the inner membrane and a concomitant 
sixteen-fold increase in the mtDNA mutation rate
61
. 
Disruption in the Complexes raises ROS production, engaging the aforementioned 
vicious cycle of increased protein and DNA damage, followed by further increase in ROS 
levels. The results are damaged or defective mitochondria and a cellular environment 
with hostile ROS interacting deleteriously with the nucleus and cytoplasm. ROS by itself 
is a key cellular death signal
62
, often released by the cell intentionally to cement its own 
demise after DNA damage.  
If the above is insufficient to kill the cell, the gradual reduction of ATP 
production may induce apoptosis in cells requiring higher energy levels. Further, once an 
energetic threshold has been reached, cells may enter senescence while up-regulating 
cellular maintenance genes
63
 and down-regulating functions related to the cell‟s 
organismal role. This senescent „house-keeping‟ stage, if repeated by a group of cells, 
may lead to tissue failure and eventually organ failure. Muscles are weakened and tone 
decreases. All these are classic hallmarks of aging. 
In a direct test of the mitochondrial theory of aging and ROS production, mice 
heterozygous for the SOD2 antioxidant gene, therefore unable to produce SOD2 at levels 
seen with wild-type mice, demonstrated increased oxidative damage but did not 
significantly decrease their lifespans. New theories, identifying ROS production as a key 
cellular signal for OXPHOS regulation
64
 and a homeostatic control, cast doubt on the 
current dietary fad of ingesting enormous amounts of antioxidants to stave off aging
65
. 
All this may do is further tax the cell by forcing it to export the compounds out of the cell 
as waste products. Further animal studies have replicated these disappointing results, and 
19 
 
meta-studies of human antioxidant consumption have found zero, to slightly negative 
health results among those with adequate base diets
66
. Therefore ROS may not be the first 
cause of mitochondrial degeneration. 
Morphologically, mitochondria in the young and aged are distinct. Whereas a 
large number of small mitochondria are present in young cells, a small number of large 
mitochondria are visible in old cells of both rats and humans, while the total volume of 
mitochondria (~20% of cell volume) remains constant
67
. The larger, old mitochondria 
respire considerably less in aged liver tissue
68
. 
Aging, as far as it is mitochondrially related, may therefore not require cell-
catastrophic levels of ROS and a vicious cycle, but the slow, inevitable creep of deletions 
of mtDNA and mutations of nuclear-encoded mitochondrial nDNA. Past an energetic 
threshold that may be determined by the degree of heteroplasmy, the cell enters 
senescence or dies. The effect on the circa 1.5% of the cells classified as stem cells is 
worthy of speculation; if large portions of these cells senesce then tissue regeneration, 
central nervous cell replenishment, muscle tone (inclusive of muscles contributing to 
tight, non-wrinkled skin), and wound healing would all be affected. These too are 
hallmarks of aging. 
If the above is true, then mammals with longevity characteristics ought to have 
evolved with lower mutation rates of mtDNA, and not necessarily reduced metabolic 
rates. A cross-species analysis found reduced mtDNA base repeats in longer-lived 
creatures; base repeats are considerably more prone to mutation
69
. Indeed, reduced 
mtDNA mutation rates were found in longer-lived animals
70
. In favour of steady-decline 
models are studies supporting the notion of widespread mtDNA deletion over time, and 
20 
 
more worryingly, rates of mutation increase in energy-intensive tissues. One paper found 
a 2,000-fold increase in cerebral mutation rates over the cerebellum, with as much as 3% 
of total mtDNA bases mutated in elderly samples
71
. Other studies have found tissue-
specific mutations that appear only in certain aging periods
72
. The process appears in 









it could be argued that mtDNA mutations and deletion might be an effect, not a cause of 
aging. 
An elegant study using homozygous knock-in mice addressed this central issue. 
Modification of the nuclear Polg polymerase, the only protein able to copy mtDNA and 
vital for tissue formation and mitochondrial operation, rendered it unable to proofread 
effectively
77
. The mice consequently suffered a far higher mutation rate of mtDNA. 
These modified mice developed classic signs of mouse aging by only 25 weeks, including 
spine kurtosis, weight and hair loss, osteoporosis, anaemia, alopecia, heart enlargement 
and sarcopenia (Figure 5). A median lifespan of 46 weeks was observed with no mouse 













The mitochondrial theory of aging does not lay claim to the entire aging effect 
and complementary theories include build-up of intracellular and intercellular wastes, 
cross-linking of compounds, ROS damage of cellular machinery, nuclear DNA mutation 
and general mis-repair accumulation
80
. Nevertheless, a therapy that could repair mtDNA, 
restore sufficient homoplasmy, and potentially reboot cells might result in measurable life 
extension and delay of age-related decay. Such an invention would have immense 
societal and economic consequences.  
 
DRUG DEVELOPMENT PROSPECTS 
Micromolecule Delivery Strategies  
As mentioned previously, access to the mitochondrial matrix is challenging due to 
the inner and outer mitochondrial membranes. Any potential drug regardless of vector 
will have to negotiate this barrier after successfully entering the cytosol through the cell‟s 
22 
 
outer membrane. Two methods have been researched: entry via the TIM/TOM membrane 
gates, and outright fusion with specially formulated liposomes.  
Using the gates requires the correct „key‟, a pre-sequence tag that is recognized by 
the gate proteins. Many exist, and are usually 10-80 amino acid residues in length and 
fold into an amphipathic α-helix with a hydrophilic and hydrophobic face
81
. Localization 
to the mitochondria is facilitated by the molecular chaperone Hsp90. Passing through the 
TOM gate, the protein‟s precursor is then cleaved by a peptidase at the TIM gate before 
accession to the inner matrix. Proteins destined for other compartments, such as the outer 
or inner membrane and intermembrane space, contain poorly understood internal 
sequencing signals.  
Drug designers pursuing this route are able to choose from viral or non-viral 
vectors for entry into the cytoplasm as long as the cargo with its pre-sequence are 
delivered intact. Designed for protein transport, the system could in theory be used for 
snippets of DNA, RNA, siRNA/miRNA, or nucleases.  
Protein import, which the system was designed to handle, may be the cargo of 
choice. A therapy might include provision of replacement or supplementary endogenous 
proteins that for reasons of mutation or mis-regulation are misshapen or in insufficient 
quantity, or supply of a custom small molecule(s) with a desired effect. The advantage of 
such small sizes is the possibility of oral dosing - key to adoption in the U.S. market
82
. 
Commercially several drugs are under development utilizing the TIM/TOM 
approach. Edison Pharmaceuticals is entering pivotal Phase 2 trials for an orally absorbed 
small molecule called EPI-743. It works as a CoQ analogue by targeting NADPH 
quinone oxidoreductase (NQO1) in Complex I, for treatment of 60 patients with Leber‟s 
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Hereditary Optic Neuropathy(LHON). The FDA granted orphan drug status to Edison for 
EPI-743. Little toxicity was noted and earlier trials demonstrated very promising 
results
83
. A second molecule is in Phase 2a, intending to treat Friedrich‟s ataxia. There do 
not appear to be other clinical trials specifically targeting mitochondria internally. The 
company does not give details out on the formulation of EPI-743, but given its definition 
as a small molecule and formulation, it is most-likely capable
84
 of passively crossing the 
mitochondrial membranes.  
Recent academic research appears to have successfully inserted macromolecules 
by packaging an mtDNA gene called ND4 inside of a plasmid and then repackaging it 
inside of an adeno-associated virus(AAV) capsid containing the AAV protein fused to a 
mitochondrial targeting sequence
85
. Injection of the construct into vitreous mouse eyes 
resulted in successful recombination of the gene and its expression of the protein in 
mouse eyes along with attendant ATP synthesis. The experiment was repeated with 
mutant, defective ND4, and the mice developed LHON-like symptoms. The authors 
speculate that given the AAV vector‟s payload capacity of up to 5,000 base pairs, large 
deletions of mtDNA could be repaired.  
However, use of such a vector implies local or temporary application due to 
immune response. The vitreous humour contains no white blood cells and is as a result a 
fertile target of gene therapy. Deployment of viral vectors elsewhere in the body will 
provoke an immune response and this has prevented use in a global treatment. Perhaps a 
non-viral vector studded with MTS could achieve a similar effect. Alternative small-
molecule delivery strategies include lipophilic cations, where the delocalized positive 




Macromolecule Delivery Strategies  
For truly large payloads, such as full, intact 16.5kb mtDNA molecule, a non-viral 
vector will be needed. Historically this has meant liposomes, dual-layer 
hydrophilic/hydrophobic lipids that resemble tiny cells with an inner core containing the 
drug of choice. These vectors feature lower immunogenicity but sacrifice transfection 
rate versus the viral approach. The inner core may be filled with a variety of compounds 
and sizing is very flexible. Intact mtDNA could be shuttled, as well as RNA, or for down-
regulation, siRNA, miRNA or nucleases targeting deleterious mutations. Alternatively a 
protein or cocktail of proteins could be considered, or a variety of small molecules. 
Structural elements of the OXPHOS Complexes could be introduced. 
 
 












Composition of the outward-facing lipid layer (Figure 6) is key to the construction of 
liposomes. It must avoid immune detection long enough to reach target tissues, and then 
competently meld with a cell‟s plasma membrane to deliver its contents, and do so 
without being engulfed by a lysosome other otherwise destroyed once inside the cytosol. 
These difficult challenges have resulted in low transfection rates for liposomes and gene 
therapy efforts are primarily viral in nature. If a global, multi-tissue delivery system is the 
goal, transfection rates will have to approach reasonable levels. Recent approaches have 
included „ghosting‟, where the outermost layer consists of remnant red blood cell 
membranes and considerably longer half-lives of the assembled liposome
87
.  
The first attempt to assemble a mitochondrially-targeted liposome began in 2003. 
A bola-liposome with a cationic outer layer was assembled, termed a DQAsome for its 
use of dequalinium chloride. The macromolecule fulfilled many of the criteria of a 
delivery system: it bound and condensed plasmid DNA, protected it from DNAse 
digestion in the cytoplasm, and successfully transported it to mitochondrial organelles. In 
vitro, cardiolipin-rich liposomal mitochondria simulants caused the DQAsomes to release 
their DNA cargo
88
. However no evidence was found of actual DNA migration into the 
inner matrix space of mitochondria and it is not obvious how a single-layer design could 




In 2008 a group of researchers from the University of Hokkaido embarked on a 
new liposomic approach involving novel multilayered liposomes entitled MITO-Porter
90
. 
Uniquely, entry into the cell is mediated by pinocytosis and not the more common 
phagocytosis. The pinocytotic pathway is generally used for smaller-sized molecular 
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import of fluids and nutrients, as opposed to the phagocytotic pathway. Pinocytosis is 
nonspecific in its import requirements. Usually the pinocytotic pathway results in 
engulfing by lysosome for degradation and digestion of the nutrients while phagocytosis 
is a key element in immune system defense and clathrin-mediated garbage collection. It 
may be speculated that reliance upon phagocytosis has been a key stumbling block in 
liposomic delivery system transfection rates due to vesicle degradation of the contents. 
Upon engulfment by the lysosome, the significance of the multi-layered nature of 
MITO-Porter is revealed. The outermost layer is dissolved upon entry to the cytosol 
through the cellular membrane, whereupon a second layer merges with the lysosome, 
facilitating escape of the macromolecule from the digestive vesicle. A third layer directs 
cellular machinery to transport the remaining liposome to mitochondrial locations, 
whereupon it melds with the mitochondrial outer membrane. A fourth and final layer 












              
 
The left side of Figure 7 demonstrates the pathway that the latest version of the MITO-
Porter platform, DF-MITO-Porter, utilizes to gain entry into the matrix.  
The Japanese research team has demonstrated steady progress in vitro of the 
technology. In 2008 a simpler single-layer octaarginine-coated liposome demonstrated 
cell entry and fusion with mitochondria, and expression of the green fluorescent protein 
(GFP) payload in mitochondrial membranes
93
. By 2010, dye whose fluorescence would 




A year later the current multilayered platform, DF-MITO-Porter was employed to 
deliver DNAse 1 into the mitochondrial inner matrix. Statistically significant reduction of 
mitochondrial respiration was observed, implying that the delivered DNAse had 
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dissolved mtDNA molecules and impaired or halted mitochondrial function as a result. 
GFP expression was confirmed by confocal laser scanning microscopy. Use of DNAse 1, 
though an elegant idea, raises the objection that respiratory decrease might have occurred 
due to nuclear DNA destruction by DNAse delivered to the nucleus incorrectly. In an e-
mail exchange, a member of the group indicated they would answer the toxicity question 
in their next study
95
. 
The team‟s latest paper, published in the summer of 2012, sought to more 
comprehensively determine delivery success rates, validate the pathway presumed to be 
the mode of action, and deliver 24-base pair oligonucleotides complexed with fluorescent 
Cy5. The inner layers of the liposome contained a mitochondria-fusogenic composition, 
while the outer envelopes were optimized for plasma membrane entry and lysosomic 
escape. Notably, no toxicity was observed with the HeLa cells used
96
.  
Using the fluorescently-tagged oligonucleotides, a more quantifiable 
understanding of liposomal fate and transfection efficiency was achieved. 83% of cells 
treated contained liposomes, up from 25% using the earlier formulation. Of these 
liposome-positive cells, only circa 20% of the oligo DNA actually arrived inside the 
mitochondria. The paper draws the conclusion that the rate-limiting step is in the cytosol: 
the liposomes enter successfully but only rarely associate with mitochondria
97
.  
In the immediate future, the team will attempt to rectify DF-MITO-Porter‟s 
cytosolic inefficiencies by experimenting with new formulations of the inner layers of the 
liposome, perhaps incorporating mitochondria targeting signals (MTS) found in nature. 
Resolution of this issue is critical to the viability of the delivery system but it does not 
appear insurmountable. There is also a potential issue with the long-term effects of a 
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successful payload delivery on an individual mitochondrion. Does such an event impair 
its voltage gradients? Further study is needed. 
A further question concerns the use of the pinocytotic pathway. Are there size 
limitations inherent in its use, and will that limit the payload that may be accommodated? 
The question will be posed at a face-to-face meeting at the World Mitochondria Congress 
in Berlin in November, 2012.  
 
Orphan Drugs Act and Mitochondrial Drug Development 
There are two primary avenues for drug development in the United States and 
abroad: large-scale, insourced drug candidates targeting diseases with large populations, 
and start-up companies associated with usually university-sourced drug candidates. The 
former model is pursued by large pharmaceutical companies, and the economics are 
daunting. Trade association PhRMA reports its members investing $49.5 billion in 
research and development in 2011
98
, and recent estimates of the total cost of a single 
new, approved drug inclusive of all other expenses such as failed drug programs, of $1.2 
billion for a novel medicine
99
.   









Ballooning costs may be due to several causes, such as reduced drug pipelines, 
diminishing returns of high-throughput screening, and perhaps most directly, increasing 
Food and Drug Administration (FDA) requirements for patient numbers and efficacy data 
during clinical trials
101
. Increased R&D allocation has not resulted in increased FDA 
approval of new drugs. Figure 8 demonstrates this alarming trend of declining novel 
medicines amid an avalanche of R&D spending. This dynamic, as well as the number of 
blockbuster drugs that are approaching the end of their patent lives and loss of attendant 
profitability have sparked a wave of acquisitions by large pharmaceutical companies of 
listed and startup biotechnology companies in an attempt to rejuvenate their product 
pipelines. It is premature to judge whether this form of insourcing of potential new 
medicines, instead of internal development, will be the saviour of the industry. 
An alternative approach to drug development lies within the rubric of the Orphan 
Drug Act passed in 1983. Given the inordinate costs of orthodox drug development, there 
is little case to be made for research of medicines for small patient populations. These so-
called orphan diseases are neglected given the risk-reward calculations biotech 
companies must make. In order for a medicine to be declared an Orphan Drug, it must be 




Once an Orphan Drug designation is achieved, numerous benefits accrue to the 
medical sponsor. The Prescription Drug User Fees Act (PDUFA) fees, required at the 
beginning of a drug approval cycle called the New Drug Application (NDA), are waived. 
For 2013, PDUFA fees stood at $2 million per drug
103
. Tax credits are available with a 
15-year carry-forward provision and a 3-year carry-back provision applied to a profitable 
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year. Further a 7-year market exclusivity is granted at the date of approval, not the date of 
the patent, and any competitor wishing to introduce a drug in the same field is forced to 
prove therapeutic superiority, not just equivalency. A policy of unified filing of ophan 
drug documents for both the FDA and the European Medicines Agency (EMA) has been 
announced
104
. Finally the FDA is required to set specific endpoints in clinical trials, that 
if reached, require it to approve the drug. Clinical trials may also be of a smaller scope 
and therefore considerably less costly
105
.  
Before 1983 only 38 drugs were approved that might be considered orphan, and 
after the legislation passed through to 2010, 353 orphan drugs were approved with 2,116 
compounds given orphan designation
106
. The global orphan drug market reached $84.9 
billion in 2009, with an estimated growth rate of 6% yearly
107
. Intriguingly a number of 
orphan drug approvals led to blockbuster, widely-utilized medicines: Abilify, Provigil, 
Vioxx, Botox and Cialis among others. Orphan designates have historically enjoyed 
considerably higher success rates and faster approval; orphans average fewer than 5 years 
from Phase 2 to market, as opposed to 6 to 8 years for conventional drugs, an 82% 
success rate from Phase 2 forward rather than 35% for traditionals, are usually first to 
market, and often address chronic diseases with lifetime dosage requirements
108
.  
Therefore an alternative model for drug development, suitable for small start-up 
companies wishing to exploit university-based research, may be to focus on a compound 
with orphan druggability. Mitochondrial diseases by their nature are an ideal target, with 
the six smallest mtDNA-related diseases accounting for circa 15,000 to 18,000 U.S. 
patients and MIDD possibly remaining just below the orphan drug limit (see Table 2). A 
drug targeting LHON will most-likely face direct competition subject to FDA approval 
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from the small molecule marketed by Edison Pharmaceuticals and perhaps Leigh‟s 
Disease ought to be a first focus for FDA approval.  
With a circa 7,500 sized patient population, Leigh‟s is characterized by movement 
disorders, continuous crying, seizures, rigidity, tremors, vomiting, and in later cases, 
lactic acidosis, kidney failure, and heart problems leading to a circa one year life 
expectancy after diagnosis
109
. The disease may be caused by either mtDNA or nDNA 
mutations. It afflicts infants, juveniles, and adults and there is no cure. As with most 
mitochondrial diseases, various combinations of CoQ10 and L-carnitine, vitamin B 




Drug pricing and business strategy is beyond the scope of this paper but in order 
to provide rough estimates of the value of monopoly positions on orphan drugs, an 
industry-standard metric called the Quality-Adjusted Life Year may be used. The World 
Health Organization considers a three times per-person income per QALY life-year 
gained to be a limit for cost-effective intervention
111
. For the United States, the 2011 per 
capita GDP of $48,100 implies a $144,300 QALY value. If 50% of the 7,500 patients 
with Leigh‟s were afflicted due to mtDNA defects, and the medicine was able to deliver 2 
years of QALY, and its nature as the only treatment available led to a 75% adoption rate, 
then the revenue value of this tiny disease stands at $750 million. Given the internal 
dynamics of the U.S. insurance system and the constitutionally validated Patient 
Protection and Affordable Care Act, a 2-QALY life-saving medicine‟s up-front cost of 
$288,600 is not an unreasonable price point. All these numbers are for the United States 
alone. Efficient development programs run parallel with the European and Japanese drug 
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approval regimes. While payouts may be decreased in these markets, if disease rates are 
constant, their total population sizes triple the patient pool
112
.   
The aforementioned numbers are not meant to be a rigorous market assessment 
but to elucidate the potential value derivable from even small orphan diseases. A 
biotechnology start-up could expedite its time to market through the orphan drug route, 
with a view to expanding the range of its official approvals after the drug has reached the 
market. In this way drug development costs may be reduced and attendant equity dilution 
of the founders reduced. Further studies, sponsored industry symposia domestically and 
abroad, and physician off-label prescriptions, as well as careful promotional policies that 
remain within FDA and Federal Trade Commission law, may provide the ground work 
for entry into major diseases such as MELAS with mitochondrial implications and 
perhaps one day, aging itself. The compelling dynamics of orphan drugs have not gone 
unnoticed in the current acquisitions spree by large pharmaceuticals; Pfizer‟s acquisition 
of Protalix for its Phase III Gaucher disease compound and Shire‟s 2005 purchase of 
Transkaryotic Therapies demonstrates the industry‟s appetite for niche drugs. 
What might a multi-disease, multi-symptom mitochondrial drug be? The 
requirements most-likely rule out small-molecule designs due to their specificity and a 
start-up‟s lack of an edge versus large pharmaceuticals‟ extensive high-throughput 
facilities. Instead a novel delivery platform of macromolecules to the mitochondria seems 








 the only academic 
candidate at this time appears to be DF-MITO-Porter. Recognition of the value of the 
drug both as the intellectual property of a flexible-compound delivery platform and 
separately as an effective mtDNA therapeutic, potentially allows for co-branding, cross-
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licencing, and other alternative financing arrangements without equity dilution. The 
above is dependent on a sufficiently impregnable patent ring with blocking capability for 
the pathways in question and a zealous legal enforcement of those patents.  
Further modification of the delivery system, such as with the addition of 
bezafibrate agonists of PCG-1α
117
, could up-regulate mitochondrial count at the same 
time that re-programming of the mitochondria with intact mtDNA or other drugs is 
undertaken. Rather than mtDNA delivery, a therapy accomplishing selective destruction 
of defective mtDNA, allowing for cellular resupply of adequate wild-type mtDNA 
molecules, could restore adequate heteroplasmy and therefore function. Finally, the 
delivery system might be re-tasked, with sufficient modification of surface compositions, 
















The significance of the „other genome‟ in medicine is only now the subject of 
extensive research. As powerhouses of the cell, mitochondria are intimately related to 
optimal cellular function and the cell death cycle. Widespread disruption of mitochondria 
through damage to mtDNA or nDNA, inherited or as a result of inevitable somatic 
processes, can cause systemic failure of high-energy tissues and crippling, currently 
incurable diseases. The process of aging itself may be partially mediated by the slow 
decay of these fascinating organelles.   
While currently unavailable, the development of a cure or treatment of a variety 
of these diseases is not impossible. Advancements in small-scale chemistry and 
nanotechnology as well as increased understanding of the basic science involved have 
opened up new, promising avenues for the treatment of mitochondrial disease. Use of the 
Orphan Drugs Act may expedite the process from lab bench to bed side, and the potential 
profit available to successful pioneers of the space may further widen the technology‟s 
applicability and potentially improve the quality of life of millions. Its pursuit is not only 
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